KRAS status as an independent prognostic factor for survival after yttrium-90 radioembolization therapy for unresectable colorectal cancer liver metastases

Journal of Vascular and Interventional Radiology

Volumn 26, Issue 8, 2015, Pages 1102-1111

  Lahti, Steven J ^a   Xing, Minzhi ^a   Zhang, Di ^b   Lee, James J ^a,c   Magnetta, Michael J ^a   Kim, Hyun S ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; K RAS PROTEIN; YTTRIUM 90; KRAS PROTEIN, HUMAN; PROTEIN P21; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER; YTTRIUM;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD PUGH SCORE; COLORECTAL LIVER METASTASIS; CONTROLLED STUDY; DEMOGRAPHY; DRUG RESPONSE; FEMALE; HUMAN; INOPERABLE CANCER; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MICROCATHETER; MUTATION RATE; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOEMBOLIZATION THERAPY; RADIOISOTOPE THERAPY; RETROSPECTIVE STUDY; AGE DISTRIBUTION; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PENNSYLVANIA; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REPRODUCIBILITY; RISK FACTOR; SECONDARY; SENSITIVITY AND SPECIFICITY; SEX RATIO; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PENNSYLVANIA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS P21(RAS); RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84938153807     PISSN: 10510443     EISSN: 15357732     Source Type: Journal    
DOI: 10.1016/j.jvir.2015.05.032     Document Type: Article

References (37)

1. Cancer Genome Atlas Research Network J.N. Weinstein, E.A. Collisson, and et al. The Cancer Genome Atlas Pan-Cancer analysis project Nat Genet 45 2013 1113 1120
2. J.L. Bos, E.R. Fearon, S.R. Hamilton, and et al. Prevalence of ras gene mutations in human colorectal cancers Nature 327 1987 293 297
3. J.L. Bos ras oncogenes in human cancer: a review Cancer Res 49 1989 4682 4689
4. S. Schubbert, K. Shannon, and G. Bollag Hyperactive Ras in developmental disorders and cancer Nat Rev Cancer 7 2007 295 308
5. E.R. Fearon, and B. Vogelstein A genetic model for colorectal tumorigenesis Cell 61 1990 759 767
6. D. Santini, F. Loupakis, B. Vincenzi, and et al. High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice Oncologist 13 2008 1270 1275
7. C.S. Karapetis, S. Khambata-Ford, D.J. Jonker, and et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer N Engl J Med 359 2008 1757 1765
8. S.T. Kim, K.H. Park, J.S. Kim, S.W. Shin, and Y.H. Kim Impact of KRAS mutation status on outcomes in metastatic colon cancer patients without anti-epidermal growth factor receptor therapy Cancer Res Treat 45 2013 55 62
9. H.J. Andreyev, A.R. Norman, D. Cunningham, and et al. Kirsten ras mutations in patients with colorectal cancer: the "RASCAL II" study Br J Cancer 85 2001 692 696
10. H.J. Andreyev, A.R. Norman, D. Cunningham, J.R. Oates, and P.A. Clarke Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study J Natl Cancer Inst 90 1998 675 684
11. S.D. Richman, M.T. Seymour, P. Chambers, and et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial J Clin Oncol 27 2009 5931 5937
12. A. Lievre, J.B. Bachet, D. Le Corre, and et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer Cancer Res 66 2006 3992 3995
13. R.G. Amado, M. Wolf, M. Peeters, and et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer J Clin Oncol 26 2008 1626 1634
14. E. Van Cutsem, C.H. Kohne, E. Hitre, and et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
15. C. Bokemeyer, I. Bondarenko, A. Makhson, and et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer J Clin Oncol 27 2009 663 671
16. J.Y. Douillard, S. Siena, J. Cassidy, and et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study J Clin Oncol 28 2010 4697 4705
17. M. Peeters, T.J. Price, A. Cervantes, and et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer J Clin Oncol 28 2010 4706 4713
18. J.Y. Douillard, K.S. Oliner, S. Siena, and et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer N Engl J Med 369 2013 1023 1034
19. V. Heinemann, L.F. von Weikersthal, T. Decker, and et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial Lancet Oncol 15 2014 1065 1075
20. J.J. Lee, and E. Chu The role of predictive molecular biomarkers for the treatment of metastatic colorectal cancer Curr Colorectal Cancer Rep 10 2014 395 402
21. R.J. Lewandowski, K.T. Sato, B. Atassi, and et al. Radioembolization with 90Y microspheres: angiographic and technical considerations Cardiovasc Intervent Radiol 30 2007 571 592
22. R. Salem, and K.G. Thurston Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations J Vasc Interv Radiol 17 2006 1251 1278
23. D.A. Kooby, V. Egnatashvili, S. Srinivasan, and et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma J Vasc Interv Radiol 21 2010 224 230
24. C.E. Atreya, R.B. Corcoran, and S. Kopetz Expanded RAS: refining the patient population J Clin Oncol 33 2015 682 685
25. L.M. Wang, A.R. Jani, E.J. Hill, and R.A. Sharma Anatomical basis and histopathological changes resulting from selective internal radiotherapy for liver metastases J Clin Pathol 66 2013 205 211
26. E. Melucci, M. Cosimelli, L. Carpanese, and et al. Decrease of survivin, p53 and Bcl-2 expression in chemorefractory colorectal liver metastases may be predictive of radiosensivity radiosensivity after radioembolization with yttrium-90 resin microspheres J Exp Clin Cancer Res 32 2013 13
27. M. Toulany, K. Dittmann, M. Kruger, M. Baumann, and H.P. Rodemann Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway Radiother Oncol 76 2005 143 150
28. M. Toulany, U. Kasten-Pisula, I. Brammer, and et al. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair Clin Cancer Res 12 2006 4119 4126
29. M. Minjgee, M. Toulany, R. Kehlbach, K. Giehl, and H.P. Rodemann K-RAS(V12) induces autocrine production of EGFR ligands and mediates radioresistance through EGFR-dependent Akt signaling and activation of DNA-PKcs Int J Radiat Oncol Biol Phys 81 2011 1506 1514
30. K. Laimer, G. Spizzo, G. Gastl, and et al. High EGFR expression predicts poor prognosis in patients with squamous cell carcinoma of the oral cavity and oropharynx: a TMA-based immunohistochemical analysis Oral Oncol 43 2007 193 198
31. S.H. Sahlberg, A.S. Gustafsson, P.N. Pendekanti, B. Glimelius, and B. Stenerlow The influence of AKT isoforms on radiation sensitivity and DNA repair in colon cancer cell lines Tumour Biol 35 2014 3525 3534
32. H. Stegeman, P.N. Span, J.H. Kaanders, and J. Bussink Improving chemoradiation efficacy by PI3-K/AKT inhibition Cancer Treat Rev 40 2014 1182 1191
33. C. Freudlsperger, D. Horn, S. Weissfuss, and et al. Phosphorylation of AKT(Ser473) serves as an independent prognostic marker for radiosensitivity in advanced head and neck squamous cell carcinoma Int J Cancer 136 2015 2775 2785
34. M. Wang, A.M. Kern, M. Hulskotter, and et al. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation Cancer Res 74 2014 2825 2834
35. M.J. Kim, H.S. Lee, J.H. Kim, and et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer BMC Cancer 12 2012 347
36. S. Misale, R. Yaeger, S. Hobor, and et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer Nature 486 2012 532 536
37. L.A. Diaz Jr, R.T. Williams, J. Wu, and et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers Nature 486 2012 537 540